222 related articles for article (PubMed ID: 25564055)
1. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
Tang X; Zhang J; Chen Y; Lan Z; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers as a diagnostic key for hilar cholangiocarcinoma.
Juntermanns B; Radunz S; Heuer M; Hertel S; Reis H; Neuhaus JP; Vernadakis S; Trarbach T; Paul A; Kaiser GM
Eur J Med Res; 2010 Aug; 15(8):357-61. PubMed ID: 20947473
[TBL] [Abstract][Full Text] [Related]
3. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.
Ohta S; Morine Y; Imura S; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Wada Y; Yamashita S; Bando Y; Shimada M
Anticancer Res; 2019 Nov; 39(11):6025-6033. PubMed ID: 31704828
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma.
Kojima S; Hisaka T; Midorikawa R; Naito Y; Akiba J; Tanigawa M; Yano H; Akagi Y; Okuda K
Anticancer Res; 2020 Aug; 40(8):4749-4754. PubMed ID: 32727801
[TBL] [Abstract][Full Text] [Related]
7. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
Zong D; Zeng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
[TBL] [Abstract][Full Text] [Related]
8. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
9. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
11. High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.
Watanabe M; Chigusa M; Takahashi H; Nakamura J; Tanaka H; Ohno T
In Vitro Cell Dev Biol Anim; 2000 Feb; 36(2):104-9. PubMed ID: 10718366
[TBL] [Abstract][Full Text] [Related]
12. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
14. [Expression of Survivin protein in extrahepatic cholangiocarcinoma and its relationship with the prognosis].
Qin XL; Xue HZ; Wang ZR; Liu HS; Zhou HB; Ma W
Zhonghua Wai Ke Za Zhi; 2009 Dec; 47(24):1852-6. PubMed ID: 20193400
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.
Kato Y; Takahashi S; Gotohda N; Konishi M
J Gastrointest Surg; 2016 Aug; 20(8):1435-43. PubMed ID: 27250990
[TBL] [Abstract][Full Text] [Related]
16. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.
Rattanasinganchan P; Leelawat K; Treepongkaruna SA; Tocharoentanaphol C; Subwongcharoen S; Suthiphongchai T; Tohtong R
World J Gastroenterol; 2006 Oct; 12(40):6500-6. PubMed ID: 17072981
[TBL] [Abstract][Full Text] [Related]
18. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Clinical Diagnostic and Prognostic Value of Preoperative Serum Carcinoembryonic Antigen, CA19-9, and CA24-2 for Colorectal Cancer.
Hou S; Jing J; Wang Y; Du L; Tian B; Xu X; Sun T; Shi Y
Altern Ther Health Med; 2023 Sep; 29(6):192-197. PubMed ID: 37295009
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
